Early and intensive treatment of age-related macular degeneration with bevacizumab is associated with greater long-term ...

Ocugen has a valuable IP portfolio, which should give it funding options. OCGN’s cash runway remains the main risk. Check out ...

Gene editing could be used to treat millions of glaucoma patients. Glaucoma is a leading cause of blindness, characterized by ...